Literature DB >> 9855627

Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani.

S Ray1, B Hazra, B Mittra, A Das, H K Majumder.   

Abstract

Diospyrin is a plant product that has significant inhibitory effect on the growth of Leishmania donovani promastigotes. This compound inhibits the catalytic activity of DNA topoisomerase I of the parasite. Like camptothecin, it induces topoisomerase I mediated DNA cleavage in vitro. Treatment of DNA with diospyrin before addition of topoisomerase I has no effect. Preincubation of topoisomerase I with diospyrin before the addition of DNA in the relaxation reaction increases this inhibition. Our results suggest that this bis-naphthoquinone compound exerts its inhibitory effect by binding with the enzyme and stabilizing the topoisomerase I-DNA "cleavable complex." Diospyrin is a specific inhibitor of the parasitic topoisomerase I. It does not inhibit type II topoisomerase of L. donovani and requires much higher concentrations to inhibit type I topoisomerase of calf thymus. The potent inhibitory effect of diospyrin on type I DNA topoisomerase from L. donovani can be exploited for rational drug design in human leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855627     DOI: 10.1124/mol.54.6.994

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  21 in total

1.  Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I.

Authors:  Arnab Roy Chowdhury; Shalini Sharma; Suparna Mandal; Anindya Goswami; Sibabrata Mukhopadhyay; Hemanta K Majumder
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

2.  An insight into the active site of a type I DNA topoisomerase from the kinetoplastid protozoan Leishmania donovani.

Authors:  Aditi Das; Chhabinath Mandal; Arindam Dasgupta; Tanushri Sengupta; Hemanta K Majumder
Journal:  Nucleic Acids Res       Date:  2002-02-01       Impact factor: 16.971

3.  Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii.

Authors:  M T Cushion; M Collins; B Hazra; E S Kaneshiro
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Evaluation of plumbagin and its derivative as potential modulators of redox thiol metabolism of Leishmania parasite.

Authors:  Neha Sharma; Anil Kumar Shukla; Mousumi Das; Vikash Kumar Dubey
Journal:  Parasitol Res       Date:  2011-06-30       Impact factor: 2.289

5.  Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin.

Authors:  M E Proulx; A Désormeaux; J F Marquis; M Olivier; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Effects of atovaquone and diospyrin-based drugs on ubiquinone biosynthesis in Pneumocystis carinii organisms.

Authors:  E S Kaneshiro; D Sul; B Hazra
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

7.  Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells.

Authors:  Marisa M Fernández; Emilio L Malchiodi; Israel D Algranati
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

8.  A Novel Spirooxindole Derivative Inhibits the Growth of Leishmania donovani Parasites both In Vitro and In Vivo by Targeting Type IB Topoisomerase.

Authors:  Sourav Saha; Chiranjit Acharya; Uttam Pal; Somenath Roy Chowdhury; Kahini Sarkar; Nakul C Maiti; Parasuraman Jaisankar; Hemanta K Majumder
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

9.  Inhibitory effects of cholesterol derivatives on DNA polymerase and topoisomerase activities, and human cancer cell growth.

Authors:  Chisato Ishimaru; Yuko Yonezawa; Isoko Kuriyama; Masayuki Nishida; Hiromi Yoshida; Yoshiyuki Mizushina
Journal:  Lipids       Date:  2008-01-24       Impact factor: 1.880

10.  Dihydrobetulinic acid induces apoptosis in Leishmania donovani by targeting DNA topoisomerase I and II: implications in antileishmanial therapy.

Authors:  Arnab Roy Chowdhury; Suparna Mandal; Anindya Goswami; Monidipa Ghosh; Labanya Mandal; Debabani Chakraborty; Agneyo Ganguly; Gayatri Tripathi; Sibabrata Mukhopadhyay; Santu Bandyopadhyay; Hemanta K Majumder
Journal:  Mol Med       Date:  2003 Jan-Feb       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.